Medscape3d
Deucravacitinib Meets Endpoints in Phase 3 PsA Trial
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Rolling Out3h
Early signs of arthritis people miss until it’s too late
Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...
Bristol Myers says over 50% responded to Sotyktu in psoriatic arthritis trial
Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...
Yonhap News Agency on MSN2d
Celltrion launches autoimmune disease treatment in U.S.
Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...
Bristol Myers announces data from Phase 3 POETYK PsA-2
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
Taiwan News2d
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.
The Pharma Letter5d
BMS data support potential for Sotyktu to impact joint and skin symptoms
US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...
Zacks.com on MSN3d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Managed Healthcare Executive11d
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available
The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.